Amgen Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Amgen Inc. - Product Pipeline Review - 2016', provides an overview of the Amgen Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Amgen Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Amgen Inc. - The report provides overview of Amgen Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Amgen Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Amgen Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Amgen Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Amgen Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Amgen Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Amgen Inc. Snapshot 7 Amgen Inc. Overview 7 Key Information 7 Key Facts 7 Amgen Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Amgen Inc. - Pipeline Review 16 Pipeline Products by Stage of Development 16 Pipeline Products - Monotherapy 17 Pipeline Products - Partnered Products 18 Pipeline Products - Out-Licensed Products 20 Amgen Inc. - Pipeline Products Glance 23 Amgen Inc. - Late Stage Pipeline Products 23 Amgen Inc. - Clinical Stage Pipeline Products 26 Amgen Inc. - Early Stage Pipeline Products 29 Amgen Inc. - Drug Profiles 33 adalimumab biosimilar 33 blinatumomab 34 darbepoetin alfa 37 denosumab 39 etanercept 42 etelcalcetide hydrochloride 44 romiplostim 46 AMG-334 48 bevacizumab biosimilar 49 evolocumab 50 fulranumab 53 panitumumab 56 rituximab biosimilar 59 romosozumab 60 trastuzumab biosimilar 62 trebananib 63 abrilumab 66 AMG-319 67 AMG-337 69 AMG-557 70 AMG-714 72 AMG-899 74 ganitumab 75 omecamtiv mecarbil MR 78 rilotumumab 81 tezepelumab 83 AMG-232 85 talimogene laherparepvec 86 AMG-172 89 AMG-208 90 AMG-211 91 AMG-224 93 AMG-228 94 AMG-282 95 AMG-301 96 AMG-330 97 AMG-357 98 AMG-581 99 AMG-592 100 AMG-595 101 AMG-780 103 AMG-811 104 AMG-820 105 AMG-876 106 AMG-900 107 AMG-XXX 109 infliximab biosimilar 110 pasotuxizumab 111 solitomab 113 AM-1638 114 AM-3189 115 AM-6226 116 AM-7209 117 AM-8553 118 AM-9514 119 AMG-0696 120 AMG-161 121 AMG-1694 122 AMG-176 123 AMG-3969 124 AMG-511 125 AMG-570 126 AMG-8718 127 AMG-986 128 Biosimilar 1 for Undisclosed Indication 129 Biosimilar 2 for Undisclosed Indication 130 Biosimilar 3 for Undisclosed Indication 131 Calcimimetic-18 132 cetuximab biosimilar 133 Drug for Atherosclerosis 134 Drugs to Inhibit FGF23 for Bone Disorders 135 Morpholinone-27 136 Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases 137 Recombinant Protein to Agonize FGFR for Type 2 Diabetes 138 Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes 139 Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes 140 Small Molecule to Agonize GPR119 for Undisclosed Indication 141 Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication 142 Small Molecule to Agonize GPR142 for Type 2 Diabetes 143 Small Molecule to Antagonize EP2 Receptor for Alzheimer Disease 144 Small Molecule to Inhibit BACE1 for Alzheimer's Disease 145 Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis 146 Small Molecule to Inhibit PI3K/mTOR for Cancer 147 Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease 148 Small Molecules to Inhibit BACE1 for Alzheimer Disease 149 Small Molecules to Inhibit PDE10A for Neurological Diseases 150 Small Molecules to Inhibit PI3K Delta for Inflammation 151 XmAb-13243 152 XmAb-13551 153 AA-71 154 Drugs for Inflammatory Bowel Disease 155 Monoclonal Antibodies for Cancer and Inflammation 156 Morpholinone-10 157 Morpholinone-16 158 Small Molecules to Inhibit CDC7 kinase for Cancer 159 Small Molecules to Inhibit IRAK-4 for Inflammation 160 Small Molecules to Inhibit NIK for Multiple Myeloma 161 Small Molecules to Inhibit Tankyrase for Cancer 162 Amgen Inc. - Pipeline Analysis 163 Amgen Inc. - Pipeline Products by Target 163 Amgen Inc. - Pipeline Products by Route of Administration 168 Amgen Inc. - Pipeline Products by Molecule Type 169 Amgen Inc. - Pipeline Products by Mechanism of Action 170 Amgen Inc. - Recent Pipeline Updates 174 Amgen Inc. - Dormant Projects 225 Amgen Inc. - Discontinued Pipeline Products 229 Discontinued Pipeline Product Profiles 230 Amgen Inc. - Company Statement 235 Amgen Inc. - Locations And Subsidiaries 237 Head Office 237 Other Locations & Subsidiaries 237 Amgen Inc. - Key Manufacturing Facilities 242 Appendix 243 Methodology 243 Coverage 243 Secondary Research 243 Primary Research 243 Expert Panel Validation 243 Contact Us 243 Disclaimer 244
List of Tables
Amgen Inc., Key Information 14 Amgen Inc., Key Facts 14 Amgen Inc. - Pipeline by Indication, 2016 16 Amgen Inc. - Pipeline by Stage of Development, 2016 23 Amgen Inc. - Monotherapy Products in Pipeline, 2016 24 Amgen Inc. - Partnered Products in Pipeline, 2016 25 Amgen Inc. - Partnered Products/ Combination Treatment Modalities, 2016 26 Amgen Inc. - Out-Licensed Products in Pipeline, 2016 27 Amgen Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 28 Amgen Inc. - Pre-Registration, 2016 30 Amgen Inc. - Filing rejected/Withdrawn, 2016 31 Amgen Inc. - Phase III, 2016 32 Amgen Inc. - Phase II, 2016 33 Amgen Inc. - Phase I, 2016 34 Amgen Inc. - Preclinical, 2016 36 Amgen Inc. - Discovery, 2016 39 Amgen Inc. - Pipeline by Target, 2016 170 Amgen Inc. - Pipeline by Route of Administration, 2016 175 Amgen Inc. - Pipeline by Molecule Type, 2016 176 Amgen Inc. - Pipeline Products by Mechanism of Action, 2016 177 Amgen Inc. - Recent Pipeline Updates, 2016 181 Amgen Inc. - Dormant Developmental Projects,2016 232 Amgen Inc. - Discontinued Pipeline Products, 2016 236 Amgen Inc., Other Locations 244 Amgen Inc., Subsidiaries 246 Amgen Inc., Key Manufacturing Facilities 249
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.